Human Trials

Tricida begins phase 3 study of TRC101 to treat metabolic acidosis associated with chronic kidney disease

Tricida announced that the first subject was enrolled in TRCA-301, a phase 3 study evaluating TRC101 in chronic kidney disease (CKD) patients with metabolic acidosis.

MD Anderson Cancer Center, Pfizer Oncology partner to assess immuno-oncology combinations in blood cancers and solid tumors

The University of Texas MD Anderson Cancer Center and Pfizer have entered into a clinical collaboration to study novel combinations of three Pfizer investigational immuno-oncology therapies and other Pfizer agents in the treatment of various solid tumors and hematologic malignancies.

Pfizer spins off new company with four rare disease therapies

US pharma giant Pfizer has spun off four investigational drugs into a new medicines company, dubbed SpringWorks Therapeutics.

Eleven Biotherapeutics completes Vicinium manufacturing for ongoing clinical trials in non-muscle invasive bladder cancer

Eleven Biotherapeutics announced that it has completed the manufacturing of all Vicinium necessary for its ongoing Phase 3 registration trial in patients with non-muscle invasive bladder cancer (NMIBC), and for its cooperative research and development agreement (CRADA) with the National Cancer Institute.

Bydureon EXSCEL trial shows favorable cardiovascular safety profile in patients with type-2 diabetes

AstraZeneca has announced full results from the EXSCEL (EXenatide Study of Cardiovascular Event Lowering) trial that showed cardiovascular safety with Bydureon (exenatide extended-release) in patients with type-2 diabetes (T2D) at a wide range of CV risk.

Vanda’s tradipitant improves itch and disease severity in patients with atopic dermatitis

Vanda Pharmaceuticals announced results from an eight-week randomized phase II clinical study of tradipitant as a monotherapy in the treatment of chronic pruritus in patients with atopic dermatitis.

AstraZeneca’s Imfinzi lung cancer drug shows significant effect in PACIFIC trial

AstraZeneca and MedImmune have presented the full PFS data from a planned interim analysis of the phase III PACIFIC trial.

IRX Therapeutics reports positive IRX-2 phase 2a head and neck squamous cell carcinoma clinical results

IRX Therapeutics has presented results from a Phase 2a clinical trial of IRX-2, the company’s lead drug candidate, in head and neck squamous cell carcinoma (SCCHN) at the European Society for Medical Oncology (ESMO) Annual Congress 2017.

Kura Oncology reports positive phase 2 study for Tipifarnib in HRAS mutant head and neck cancer

Kura Oncology has announced positive topline results from a phase 2 trial for its lead product candidate, tipifarnib, in patients with HRAS mutant relapsed or refractory squamous cell carcinomas of the head and neck (HNSCC).